Spire Wealth Management Acquires Shares of 8,949 Structure Therapeutics Inc. (NASDAQ:GPCR)

Spire Wealth Management purchased a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 8,949 shares of the company's stock, valued at approximately $243,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of GPCR. GAMMA Investing LLC grew its holdings in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after buying an additional 1,122 shares during the last quarter. Assetmark Inc. lifted its position in Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after acquiring an additional 719 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Structure Therapeutics during the 4th quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock worth $158,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC purchased a new stake in shares of Structure Therapeutics in the third quarter worth approximately $202,000. Institutional investors own 91.78% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on GPCR shares. Stifel Nicolaus began coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $81.29.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock traded down $3.11 during trading hours on Monday, hitting $24.29. 1,401,131 shares of the company's stock traded hands, compared to its average volume of 833,191. The company has a fifty day simple moving average of $29.21 and a 200-day simple moving average of $34.91. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -32.82 and a beta of -2.75. Structure Therapeutics Inc. has a 12-month low of $23.50 and a 12-month high of $62.74.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.